Microbiota Transplant Therapy Is Safe and Feasible in Pulmonary Arterial Hypertension

作者：Daphne Moutsoglou, Madelyn Blake, Dina C Belhasan, Gretchen Peichel, Brenda M. Vang, Ε. Kenneth Weir, Sharon Lopez, Kurt W. Prins, Amanda J. Kabage, Sasha Z. Prisco, Benjamin P. Kremer, Alexander Khoruts, Thenappan Thenappan · 发表于：JACC Basic to Translational Science · 年份：2025 · DOI：10.1016/j.jacbts.2025.101347 · 被引用次数：4 · 研究领域：Transplantation: Methods and Outcomes、Pulmonary Hypertension Research and Treatments、Mechanical Circulatory Support Devices

Pulmonary arterial hypertension (PAH) is a complex inflammatory disease that the gut microbiome likely contributes to and may be a potential therapeutic avenue for nontoxically improving outcomes. Here, we show that microbiota transplant therapy (MTT) is safe and feasible. The MTT regimen achieves only modest levels of donor microbiota engraftment but is accompanied by a transient reduction in circulating pro-inflammatory cytokines. These findings of decreased systemic inflammation with only modest donor engraftment support the potential of MTT as a novel treatment for PAH. (Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study; NCT04884971).